MEDIAN Technologies awarded € 1.4 million contract
MEDIAN Technologies has been selected to provide its imaging solutions in a phase II clinical trial sponsored by a leading biopharmaceutical company.
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions provider in a new phase II clinical trial for a global biopharmaceutical company.
As part of the project, imaging data will be acquired in more than 100 clinical sites located in 14 countries worldwide. Anticipated total enrollment is 300 patients with a forecasted project start by year end.
Project amount is estimated at €1.4 M (eq. $1.8 M) for MEDIAN.
“We are enthusiastic about this success. It provides further proof of our commitment to supply biopharma companies with the leading edge tools, expertise and services needed to increase productivity and improve patients’ lives.” said Fredrik Brag, CEO of MEDIAN Technologies.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”